ArticleSurgical endoscopy2026
Da Vinci single-port-assisted subcostal esophagectomy (SP SC RAMIE) - a promising SP approach.
Article in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- New access to intraluminal gastric pathologies: the SP da Vinci transgastric approach.Surgical endoscopy · 2026Article
- First series of da Vinci single-port robotic-assisted cervical oesophagectomy: single-centre IDEAL stage 2a/2b study.BJS open · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSingle-port subcostal robotic-assisted minimally invasive Ivor Lewis esophagectomy (SP SC RAMIE) offers advantages in esophageal cancer surgery but remains unfamiliar and requires a long learning curve. This retrospective case series study evaluates its feasibility, safety, and short-term outcomes.
methodsThe first 25 consecutive SP SC RAMIE procedures were analyzed. Patient demographics, neoadjuvant therapy, resection margins, lymph node yield, intraoperative parameters, postoperative recovery, complications, and mortality were assessed. Feasibility was defined by achieving R0 resection and a lymph node yield exceeding benchmark recommendations.
resultsThe cohort consisted primarily of male patients with adenocarcinoma of the esophagogastric junction, 72% of whom had undergone neoadjuvant therapy. R0 resection was achieved in all cases, with a mean lymph node yield of 30 (SD ± 10), confirming procedural feasibility. Mean total operative time was 324 (± 51) minutes, with an active console time of 79 (± 17) minutes. No intraoperative complications or conversions occurred. No patient received epidural or intercostal catheter analgesia and mean postoperative pain scores were very low. By postoperative day five, 92% of patients were receiving analgesia on demand. Most patients ambulated on the first postoperative day, and the median hospital stay was seven days (range 5-40). Postoperative complications included two cases of pneumonia (8%) and two anastomotic leakages (8%), all managed endoscopically with an endoluminal vacuum sponge. In-hospital, 30-day, and 90-day mortality rates were 0%.
conclusionsSP SC RAMIE is a feasible and safe esophagectomy technique for lower esophageal cancer resection, with a low complication rate and high lymph node retrieval. Rapid recovery, low pain scores, and a short hospital stay highlight its potential benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.